Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. METHODS: ODYSSEY OUTCOMES (Evaluation of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Circulation
Glavni autori: Steg, Philippe Gabriel, Szarek, Michael, Bhatt, Deepak L., Bittner, Vera A., Brégeault, Marie-France, Dalby, Anthony J., Diaz, Rafael, Edelberg, Jay M., Goodman, Shaun G., Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W., Moryusef, Angèle, Ostadal, Petr, Parkhomenko, Alexander, Pordy, Robert, Roe, Matthew T., Tricoci, Pierluigi, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Schwartz, Gregory G.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2019
Teme:
Original Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6661243/
https://ncbi.nlm.nih.gov/pubmed/31117810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.038840
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items